Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (251-260 of 313) with videos related to

Pageof 32
Sort By:
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|February 22, 2021
Usefulness of Rhythm Monitoring Following Acute Ischemic StrokeShaan Khurshid, Xinye Li, Jeffrey M Ashburner, et al.
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
American Heart Journal|December 9, 2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillationSean D Pokorney, DaJuanicia N Holmes, Peter Shrader, et al.
Pageof 32

Showing results (251-260 of 313) with videos related to

Sort By:
Pageof 32
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|February 22, 2021
Usefulness of Rhythm Monitoring Following Acute Ischemic StrokeShaan Khurshid, Xinye Li, Jeffrey M Ashburner, et al.
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
American Heart Journal|December 9, 2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillationSean D Pokorney, DaJuanicia N Holmes, Peter Shrader, et al.
Pageof 32